Susquehanna initiates coverage on Synta Pharmaceuticals (NASDAQ: SNTA) with a Positive rating and a $16 price target.

This article: 110 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE